{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T17:32:37Z","timestamp":1781976757808,"version":"3.54.5"},"reference-count":47,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Little is known regarding the non-inferiority of new anti-seizure medications (ASMs) in terms of replacing valproic acid (VPA) in patients with idiopathic generalized epilepsy (IGE). We hypothesized that replacement of VPA with new ASMs would offer non-inferior or better control of seizure frequency. The purpose of this study was to compare epileptic seizure frequency between the subset of patients with IGE who were on VPA and the subset of patients with IGE who replaced VPA with new ASMs. Methods: Patients with IGE who were on or had been on VPA between January 2016 and March 2022 were divided into a group that replaced VPA with new ASMs (VPA-replace group) and a group that remained on VPA (VPA-continue group). We then compared the groups in terms of seizure frequency and myoclonus. Results: Of the 606 patients on VPA between January 2016 and March 2022, 156 patients with IGE were enrolled to this study (VPA-replace group, n = 68; VPA-continue group, n = 88). The VPA-replace group included significantly more females than the VPA-continue group (p &lt; 0.001). The VPA-replace group also showed significantly higher seizure frequency before replacement (p &lt; 0.001), but not after replacement (p = 0.074). Patients on monotherapy displayed improved seizure frequency with new ASMs (p &lt; 0.001). Among the new ASMs, perampanel (PER) significantly improved seizure frequency (p = 0.002). Forty-two patients in the VPA-replace group who had myoclonus achieved significant improvements (p &lt; 0.001). Among these, patients on PER monotherapy (p &lt; 0.001) or PER + lamotrigine (0.016) showed significantly improved myoclonus scale scores. Conclusions: This study shows the non-inferiority of new ASMs compared to VPA, with better seizure control using new ASMs in subsets of patients with IGE on monotherapy.<\/jats:p>","DOI":"10.3390\/jcm11154582","type":"journal-article","created":{"date-parts":[[2022,8,7]],"date-time":"2022-08-07T22:51:46Z","timestamp":1659912706000},"page":"4582","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Replacement of Valproic Acid with New Anti-Seizure Medications in Idiopathic Generalized Epilepsy"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5308-2965","authenticated-orcid":false,"given":"Ayataka","family":"Fujimoto","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Seirei Hamamatsu General Hospital, 2-12-12 Sumiyoshi, Nakaku, Hamamatsu 430-8558, Japan"},{"name":"Comprehensive Epilepsy Center, Seirei Hamamatsu General Hospital, 2-12-12 Sumiyoshi, Nakaku, Hamamatsu 430-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Enoki","sequence":"additional","affiliation":[{"name":"Comprehensive Epilepsy Center, Seirei Hamamatsu General Hospital, 2-12-12 Sumiyoshi, Nakaku, Hamamatsu 430-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6054-120X","authenticated-orcid":false,"given":"Keisuke","family":"Hatano","sequence":"additional","affiliation":[{"name":"Comprehensive Epilepsy Center, Seirei Hamamatsu General Hospital, 2-12-12 Sumiyoshi, Nakaku, Hamamatsu 430-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keishiro","family":"Sato","sequence":"additional","affiliation":[{"name":"Comprehensive Epilepsy Center, Seirei Hamamatsu General Hospital, 2-12-12 Sumiyoshi, Nakaku, Hamamatsu 430-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3295-2236","authenticated-orcid":false,"given":"Tohru","family":"Okanishi","sequence":"additional","affiliation":[{"name":"Comprehensive Epilepsy Center, Seirei Hamamatsu General Hospital, 2-12-12 Sumiyoshi, Nakaku, Hamamatsu 430-8558, Japan"},{"name":"Division of Child Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Yonago 683-8503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S1734-1140(09)70024-6","article-title":"Third-Generation Antiepileptic Drugs: Mechanisms of Action, Pharmacokinetics and Interactions","volume":"61","author":"Luszczki","year":"2009","journal-title":"Pharm. Rep"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1212\/WNL.0000000000005756","article-title":"Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society","volume":"91","author":"Kanner","year":"2018","journal-title":"Neurology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/epi4.12268","article-title":"Brief History of Anti-Seizure Drug Development","volume":"3","author":"Rho","year":"2018","journal-title":"Epilepsia Open"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/2042098611411127","article-title":"New Generation Antiepileptic Drugs: What Do They Offer in Terms of Improved Tolerability and Safety?","volume":"2","author":"French","year":"2011","journal-title":"Ther. Adv. Drug Saf."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1038\/s41598-017-02525-2","article-title":"Efficacy and Tolerability of Second and Third Generation Anti-epileptic Drugs in Refractory Epilepsy: A Network Meta-Analysis","volume":"7","author":"Zhuo","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1080\/14737175.2016.1195264","article-title":"Third Generation Antiepileptic Drug Monotherapies In Adults With Epilepsy","volume":"16","author":"Mula","year":"2016","journal-title":"Expert Rev Neurother"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/psyg.12463","article-title":"Activities Of Daily Living Are Associated With Outcomes Of Epilepsy Treatment In Elderly Patients","volume":"20","author":"Fujimoto","year":"2020","journal-title":"Psychogeriatrics"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/20786190.2016.1148337","article-title":"Anti-Epileptic Prescribing Patterns in the South African Private Health Sector (2008\u20132013)","volume":"58","author":"Jacobs","year":"2016","journal-title":"S. Afr. Fam. Pract."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/archneurol.2012.2203","article-title":"Substitution Monotherapy With Levetiracetam vs Older Antiepileptic Drugs: A Randomized Comparative Trial","volume":"69","author":"Hakami","year":"2012","journal-title":"Arch Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2165\/00148581-200608020-00004","article-title":"Valproate as a Mainstay of Therapy for Pediatric Epilepsy","volume":"8","author":"Guerrini","year":"2006","journal-title":"Pediatric Drugs"},{"key":"ref_11","first-page":"75","article-title":"The Relationship Between Treatment With Valproate, Lamotrigine, and Topiramate and the Prognosis of the Idiopathic Generalised Epilepsies","volume":"75","author":"Nicolson","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3390\/pediatric13040078","article-title":"Therapeutic Options for Childhood Absence Epilepsy","volume":"13","author":"Rinaldi","year":"2021","journal-title":"Pediatric Rep."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Mishra, M.K., Kukal, S., Paul, P.R., Bora, S., Singh, A., Kukreti, S., Saso, L., Muthusamy, K., Hasija, Y., and Kukreti, R. (2022). Insights into Structural Modifications of Valproic Acid and Their Pharmacological Profile. Molecules, 27.","DOI":"10.3390\/molecules27010104"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.seizure.2021.06.033","article-title":"Initial Levetiracetam Versus Valproate Monotherapy in Antiseizure Medicine (ASM)-Na\u00efve Pediatric Patients with Idiopathic Generalized Epilepsy with Tonic-Clonic Seizures","volume":"91","author":"Abdelmesih","year":"2021","journal-title":"Seizure"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s11096-018-0641-9","article-title":"Comparative Efficacy of Antiepileptic Drugs for Patients with Generalized Epileptic Seizures: Systematic Review and Network Meta-Analyses","volume":"40","author":"Campos","year":"2018","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1528-1167.2005.00322.x","article-title":"Management Guidelines for Children with Idiopathic Generalized Epilepsy","volume":"46","author":"Camfield","year":"2005","journal-title":"Epilepsia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0140-6736(21)00246-4","article-title":"The SANAD II Study of the Effectiveness and Cost-Effectiveness of Valproate Versus Levetiracetam for Newly Diagnosed Generalised and Unclassifiable Epilepsy: An Open-Label, Non-Inferiority, Multicentre, Phase 4, Randomised Controlled Trial","volume":"397","author":"Marson","year":"2021","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/j.1528-1167.2006.00585.x","article-title":"ILAE Treatment Guidelines: Evidence-Based Analysis of Antiepileptic Drug Efficacy and Effectiveness as Initial Monotherapy for Epileptic Seizures and Syndromes","volume":"47","author":"Glauser","year":"2006","journal-title":"Epilepsia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/epi4.12349","article-title":"Comparative Effectiveness of Antiepileptic Drugs in Juvenile Myoclonic Epilepsy","volume":"4","author":"Silvennoinen","year":"2019","journal-title":"Epilepsia Open"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"French, J.A., Wechsler, R.T., Trinka, E., Brandt, C., O\u2019Brien, T.J., Patten, A., Salah, A., and Malhotra, M. (2022). Long-Term Open-Label Perampanel: Generalized Tonic-Clonic Seizures In Idiopathic Generalized Epilepsy. Epilepsia Open.","DOI":"10.1002\/epi4.12602"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/epi.16548","article-title":"Effectiveness and Safety of Perampanel Monotherapy for Focal and Generalized Tonic-Clonic Seizures: Experience from A National Multicenter Registry","volume":"61","author":"Santamarina","year":"2020","journal-title":"Epilepsia"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/ane.12931","article-title":"Retrospective Study of Perampanel Efficacy and Tolerability in Myoclonic Seizures","volume":"138","author":"Montoya","year":"2018","journal-title":"Acta Neurol. Scand."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.2169\/internalmedicine.7295-21","article-title":"Efficacy of Lacosamide in a Patient with Refractory Generalized Epilepsy Based on Video Electroencephalography","volume":"60","author":"Yamada","year":"2021","journal-title":"Intern. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"370","author":"Altman","year":"2007","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"642","DOI":"10.4088\/JCP.v66n0516","article-title":"Dermatology Precautions and Slower Titration Yield Low Incidence of Lamotrigine Treatment-Emergent Rash","volume":"66","author":"Ketter","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"677828","DOI":"10.3389\/fneur.2021.677828","article-title":"Patients With Epilepsy Who Underwent Epilepsy Surgery During the COVID-19 Pandemic Showed Less Depressive Tendencies","volume":"12","author":"Niimi","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/mds.870110615","article-title":"Clinical Trial of Piracetam in Patients with Myoclonus: Nationwide Multiinstitution Study in Japan","volume":"11","author":"Ikeda","year":"1996","journal-title":"Mov. Disord."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.clinph.2019.07.006","article-title":"Low-Dose Perampanel Improves Refractory Cortical Myoclonus By the Dispersed And Suppressed Paroxysmal Depolarization Shifts in the Sensorimotor Cortex","volume":"130","author":"Oi","year":"2019","journal-title":"Clin. Neurophysiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1212\/WNL.0000000000001772","article-title":"Dose-dependent teratogenicity of valproate in mono- and polytherapy: An observational study","volume":"85","author":"Tomson","year":"2015","journal-title":"Neurology"},{"key":"ref_30","first-page":"Cd010236","article-title":"Treatment for Epilepsy in Pregnancy: Neurodevelopmental Outcomes in the Child","volume":"2014","author":"Bromley","year":"2014","journal-title":"Cochrane. Database. Syst. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ntt.2016.01.001","article-title":"Behavioral Outcomes in Children Exposed Prenatally to Lamotrigine, Valproate, or Carbamazepine","volume":"54","author":"Deshmukh","year":"2016","journal-title":"Neurotoxicology Teratol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1007\/s00415-020-09809-0","article-title":"Expert Opinion: Use of Valproate in Girls and Women of Childbearing Potential with Epilepsy: Recommendations and Alternatives Based on a Review of the Literature and Clinical Experience-a European Perspective","volume":"268","author":"Toledo","year":"2021","journal-title":"J. Neurol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/epi4.12228","article-title":"Valproic Acid Utilization Among Girls and Women in Stockholm: Impact of Regulatory Restrictions","volume":"3","author":"Komen","year":"2018","journal-title":"Epilepsia Open"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"B\u0142aszczyk, B., Miziak, B., Pluta, R., and Czuczwar, S.J. (2022). Epilepsy in Pregnancy\u2014Management Principles and Focus on Valproate. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031369"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/j.yebeh.2013.01.001","article-title":"Management of Juvenile Myoclonic Epilepsy","volume":"28","author":"Crespel","year":"2013","journal-title":"Epilepsy Behav."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Proposal for Revised Classification of Epilepsies and Epileptic Syndromes (1989). Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia, 30, 389\u2013399.","DOI":"10.1111\/j.1528-1157.1989.tb05316.x"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1600-0404.2007.00848.x","article-title":"Is Vagus Nerve Stimulation a Treatment Option for Patients with Drug-Resistant Idiopathic Generalized Epilepsy?","volume":"187","author":"Kostov","year":"2007","journal-title":"Acta Neurol. Scand. Suppl"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1212\/01.wnl.0000174517.21383.36","article-title":"Lamotrigine Associated with Exacerbation or De Novo Myoclonus in Idiopathic Generalized Epilepsies","volume":"65","author":"Crespel","year":"2005","journal-title":"Neurology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"106191","DOI":"10.1016\/j.eplepsyres.2019.106191","article-title":"An Italian Multicentre Study of Perampanel in Progressive Myoclonus Epilepsies","volume":"156","author":"Canafoglia","year":"2019","journal-title":"Epilepsy Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/epi.13662","article-title":"Perampanel in 12 Patients with Unverricht-Lundborg Disease","volume":"58","author":"Crespel","year":"2017","journal-title":"Epilepsia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.clinph.2021.01.018","article-title":"Cortico-muscular and Cortico-Cortical Coherence Changes Resulting from Perampanel Treatment in Patients with Cortical Myoclonus","volume":"132","author":"Franceschetti","year":"2021","journal-title":"Clin. Neurophysiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/epi.13355","article-title":"Neocortical Gamma Oscillations In Idiopathic Generalized Epilepsy","volume":"57","author":"Benedek","year":"2016","journal-title":"Epilepsia"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/jnnp.57.7.797","article-title":"In Vivo Demonstration of Altered Benzodiazepine Receptor Density in Patients with Generalised Epilepsy","volume":"57","author":"Savic","year":"1994","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/j.1528-1157.1997.tb01198.x","article-title":"Central Benzodiazepine\/Gamma-Aminobutyric Acid a Receptors in Idiopathic Generalized Epilepsy: An [11C]Flumazenil Positron Emission Tomography Study","volume":"38","author":"Koepp","year":"1997","journal-title":"Epilepsia"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1586\/17512433.2015.1091303","article-title":"Perampanel in the Treatment of Focal and Idiopathic Generalized Epilepsies and of Status Epilepticus","volume":"8","author":"Strzelczyk","year":"2015","journal-title":"Expert Rev. Clin. Pharm."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1111\/j.1528-1167.2010.02569.x","article-title":"Alteration of Dopamine D2\/D3 Receptor Binding in Patients with Juvenile Myoclonic Epilepsy","volume":"51","author":"Landvogt","year":"2010","journal-title":"Epilepsia"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1046\/j.1528-1157.2002.09902.x","article-title":"Topiramate Selectively Decreases Intracortical Excitability in Human Motor Cortex","volume":"43","author":"Reis","year":"2002","journal-title":"Epilepsia"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/15\/4582\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:04:42Z","timestamp":1760141082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/15\/4582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":47,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["jcm11154582"],"URL":"https:\/\/doi.org\/10.3390\/jcm11154582","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,5]]}}}